Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 multiple-dose study of NS-050/NCNP-03 in boys with Duchenne muscular dystrophy
jRCT2041240060Phase 2Recruiting
- Sponsor
- NS Pharma, Inc.
- Start
- Sep 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised trial of NS-050 in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by NS Pharma, Inc. Primary endpoint: Biceps brachii muscle dystrophin protein by Western blot. Started Sep 2024; status: recruiting.
02
Drugs
NS-050
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on jRCT2041240060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240060.